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Atopic dermatitis (AD) affects adults and children and 
has a negative impact on quality of life. The present mul-
ticentre randomized double-blind controlled trial show-
ed a barrier-improving cream (5% urea) to be superior 
to a reference cream in preventing eczema relapse in pa-
tients with AD (hazard ratio 0.634, p = 0.011). The risk of 
eczema relapse was reduced by 37% (95% confidence in-
terval (95% CI) 10–55%). Median time to relapse in the 
test cream group and in the reference cream group was 
22 days and 15 days, respectively (p = 0.013). At 6 months 
26% of the patients in the test cream group were still 
eczema free, compared with 10% in the reference cream 
group. Thus, the barrier-improving cream significantly 
prolonged the eczema-free time compared with the re-
ference cream and decreased the risk of eczema relapse. 
The test cream was well tolerated in patients with AD. 
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Atopic dermatitis (AD) is a common chronic inflamma-
tory skin diseases affecting up to 10% of adults and 30% 
of children in the Western world (1). It is a multifactorial 
disease, which is influenced by inheritance as well as by 
the environment. AD is a relapsing and remitting disease 
with exacerbations. It has a considerable impact on the 
patient’s quality of life (QoL) (2). Patients with AD have 
defects in skin barrier function, resulting in reduced water 
retention. The defected skin barrier also predisposes the 
skin to increased susceptibility to noxious substances, 
and may lead to allergies and asthma (3, 4).
In addition to the elimination of provoking factors, 
conventional therapy in the acute phase of AD is based 
on anti-inflammatory drugs, usually topical glucocorti-
coids or calcineurin inhibitors, combined with moisturi-
zer treatment (5). The use of moisturizers is emphasized 
by healthcare professionals as part of the treatment of 
AD (6–8). Moisturizer therapy is suggested to enhance 
the healing of eczemas (9, 10) and to prolong the clinical 
improvement after discontinuation of anti-inflammatory 
therapy (11), thereby reducing the need for additional 
treatment, including topical corticosteroids (12). 
Selecting the most suitable moisturizer for treatment 
of AD has been a matter of trial-and-error, since the be-
neficial effects of most moisturizers on skin barrier func-
tion are not well documented. Some moisturizers have 
even been shown to worsen the skin barrier function on 
normal skin (13–15). The test cream used in this study 
is a medicinal moisturizer with 5% urea (Canoderm, 
ACO Hud Nordic, Sweden), which has been shown to 
improve skin barrier function, as measured by a reduced 
transepidermal water loss (TEWL) and skin susceptibi-
lity to surfactant-induced irritation, in AD as well as in 
normal skin (13, 16–19). The test cream has also been 
shown to delay time to eczema-relapse in patients with 
eczema, compared with no treatment (20, 21). 
To our knowledge, no randomized controlled double-
blind clinical studies have been done comparing the 
time to eczema-relapse with a barrier-strengthening 
moisturizer and a moisturizer without a measurable ef-
fect on skin barrier function in maintenance treatment. 
It was therefore important to evaluate this in order to 
facilitate an evidence-based choice of moisturizer. 
The primary objective of this study was to show that a 
barrier-strengthening moisturizer (test cream), is supe-
rior to a reference cream (without urea), in preventing 
eczema relapse in patients with AD.
PATIENTS AND METHODS
Study design
This multicentre study consisted of 2 phases, an open-label 
stabilization phase and a double-blind randomized, prospective 
and parallel group maintenance phase (visit 2/2b [randomiza-
tion and start of maintenance phase], visit 3 [day 28 ± 5 days] 
and visit 4 [day 180 ± 14 days] or until relapse occurred). Pa-
tients were recruited at 15 dermatological clinics in Finland, 
Comparison of Moisturizing Creams for the Prevention of Atopic 
Dermatitis Relapse: A Randomized Double-blind Controlled 
Multicentre Clinical Trial 
Ulf ÅKERSTRÖM1, Sakari REITAMO2, Tor LANGELAND3, Mats BERG4, Lisbeth RUSTAD5, Laura KORHONEN6, Marie LODÉN7, 
Karin WIRÉN1, Mats GRÄNDE1, Petra SKARE1 and Åke SVENSSON8
1Department of Innovation, ACO Hud Nordic AB, Upplands Väsby, Sweden, 2Skin and Allergy Hospital, University of Helsinki, Helsinki, Finland, 3Hudlege 
Tor Langelands kontor, Oslo, Norway, 4Department of Dermatology, Mälar Hospital, Eskilstuna, Sweden, 5Department of Dermatology, Haukeland University 
Hospital, Bergen, Norway, 6Allergy Centre and Department of Dermatology, Tampere University Hospital, Tampere, Finland, 7Eviderm Institute AB, Solna, 
and 8Department of Dermatology, Skåne University Hospital, Malmö, Sweden
588 U. Åkerström et al.
Norway and Sweden. All participants received oral and written 
information about the study and voluntarily signed an informed 
consent. The study was planned and carried out with the ethical 
principles of the latest revision of the Declaration of Helsinki 
as adopted by the World Medical Association and good clinical 
practice. The protocol was approved by local ethics commit-
tees and by the Medical Products’ Agencies in participating 
countries. The study was conducted during the period from 
September 2011 to September 2012.
Patients
Inclusion criteria were: subjects ≥ 18 years old, diagnosed with 
AD according to UK working party’s criteria 1994 and with 
visible atopic eczema of the body surface area, corresponding 
to a total area of at least the size of the palm of one hand. 
Exclusion criteria were: eczema exclusively on the hands, any 
concomitant medications that might affect the study’s outcome, 
known hypersensitivity or allergy to any of the study products, 
any serious current medical condition that could interfere 
with the evaluation of the study results, patients assessed by 
the investigator to have poor compliance, enrolled in any in-
vestigational study or using an investigational drug within 3 
months prior to the screening visit. Patients who were pregnant, 
breastfeeding, or planning to become pregnant during the study 
time, were also excluded. Patients were randomized at visit 
2/2b. Randomization to test cream and reference cream groups 
in 1:1, was performed according to a randomization list, with a 
block size of 4, and stratified for country with one randomiza-
tion list for each country. The patients were provided with a 
randomization number. The randomization was prepared by an 
independent statistician using a validated SAS® program. All 
study personnel at the clinics and the sponsor staff remained 
blinded during the maintenance part of the study.
Interventions
At the screening visit (visit 1), the following assessments were 
performed: severity of AD (Rajka & Langeland; 22), evalua-
tion of the eczemas (SCORing Atopic Dermatitis [SCORAD]) 
and QoL (EQ-5D). The study area eczemas were defined 
(SCORAD) and patients entered the stabilization phase during 
which the study areas were treated with once-daily topical mo-
metasone furoate cream 0.1% (Elocon, Merck Sharp & Dohme 
B.V, Netherlands) on the trunk and extremities and/or hydro-
cortisone cream 1% (Hyderm® ACO Hud Nordic, Upplands 
Väsby, Sweden) on the face, groins and armpits. In addition, 
patients used a medicinal moisturizer containing 20% glycerol 
(Miniderm®, ACO Hud Nordic, Upplands Väsby, Sweden) on 
the study areas as well as on other dry areas as needed. At visit 
2, evaluation of eczemas (SCORAD) and QoL (EQ-5D) was 
performed and patients were also evaluated by the Investigator’s 
Global Assessment (IGA). Patients with cleared or almost 
cleared eczemas entered the maintenance phase. Patients with 
on-going eczema continued in the stabilization phase for an 
additional week before re-evaluation (visit 2b).
During the maintenance phase the test cream or the reference 
cream (ACO Hud Nordic AB, Upplands Väsby, Sweden) were 
applied at least twice daily on the study areas and on other dry 
areas until eczema relapsed (relapse visit) or until the end of 
the maintenance phase (visit 4), whichever came first. Relapse 
was defined as an episode that, from the patient’s perspective, 
required escalation of treatment of the study areas. The patients 
were instructed to contact the investigator immediately if any 
study area relapsed or if any new eczematous area appeared. 
The relapse was confirmed by the investigator using IGA and 
SCORAD. At the relapse visit, QoL (EQ-5D) was also measu-
red. Patients without any relapse continued in the study until day 
180 (visit 4) and were evaluated by IGA; SCORAD and EQ-5D.
Efficacy endpoints
The primary endpoint of the study was time between randomi-
zation and a subsequent event of relapse, measured as a hazard 
ratio. The hazard ratio is an expression of the hazard of events 
occurring in the reference cream group as ratio of the hazard 
of events occurring in the test cream group. 
Secondary endpoints were time to relapse evaluated by 
Kaplan–Meier estimator, proportions of patients still eczema 
free after 3 and 6 months maintenance treatment, absolute and 
relative risk reduction, cream consumption of maintenance 
treatment and QoL. 
During the maintenance phase, the study areas were evaluated 
by IGA and SCORAD at visit 2, visit 3, visit 4, and at the relapse 
visit. All patients were evaluated at visit 2, possibly visit 3 (de-
pending on when the relapse occurred in time) and then either at 
the relapse visit or visit 4. Patient’s QoL was assessed at visits 
1–4 using the EQ-5D™ health questionnaire of 5 dimensions 
(mobility, self-care, usual activities, pain/discomfort, anxiety/
depression) and the visual analogue scale (VAS). 
Reference and test cream
The reference cream used in this study was the placebo to the 
moisturizer Miniderm i.e. the reference cream was Miniderm 
without glycerol (ACO Hud Nordic, Upplands Väsby, Sweden). 
The reference cream has been studied clinically on atopic 
patients (23) and on normal healthy individuals showing no 
measurable effects on skin barrier function (24) and contains: 
white soft paraffin, hydrogenated canola oil, light liquid pa-
raffin, glyceryl stearate, polyoxyethylene stearate, cetostearyl 
alcohol, hard paraffin, dimethicone, cholesterol, propyl- and 
methyl parahydroxybenzoate and purified water. The test cream 
is a medicinal cream, Canoderm® (ACO Hud Nordic, Upplands 
Väsby, Sweden), available in the Nordic countries, which is 
an oil-in-water emulsion containing 5% urea, fractionated 
coconut oil, polysorbate 60, hydrogenated canola oil, propy-
lene glycol, carbomer, dimethicone, hard paraffin, glyceryl 
polymethacrylate, propyl- and methyl parahydroxybenzoate, 
sodium lactate, lactic acid, glyceryl stearate, polyoxyethylene 
stearate, cetostearyl alcohol and purified water. 
Safety
Safety was assessed by recording adverse events (AE) at all 
visits. Any new eczema that appeared on the body ≥ 5 cm from 
study areas during the maintenance phase was documented 
as an AE. Relapse was defined as an episode that, from the 
patient’s perspective, required escalation of treatment of the 
study areas. Any relapse was confirmed by the investigator by 
IGA and by SCORAD. The patients were instructed to contact 
the investigator immediately if any study area eczema relapsed 
or if any new eczema appeared on the body. The investigator 
estimated if it was a relapse of a study area eczema or if it was 
a new eczema. New eczemas were reported as AEs and the 
patient continued in the study until study area eczema relapse 
or 6 months, whichever came first. 
Statistical methods 
For the sample size determination the median time to relapse, 
based on a previous study (20), was estimated to be 3 months 
in patients treated with test cream and 1.8 months for patients 
treated with reference cream. This gives a hazard rate of 0.23 
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for test cream and 0.38 for reference cream, 
and a resulting hazard ratio of 1.65. 
It was calculated that, for a fixed follow-up 
time of 6 months, a total of 125 events or 152 
patients would provide 80% power to detect a 
hazard ratio of 1.65 at the 5% significant level 
(2-sided). All calculations were performed 
with software East® version 5.3. The event 
rate function for an exponential distribution 
is given by S(t)=e-λt,≥0, where λ is the hazard 
function, which does not change with time (t).
An interim analysis was to be performed 
if the recruitment rate was much slower than 
expected. Since the recruitment rate was as 
expected no interim analysis was performed 
in accordance with the clinical study protocol.
The primary statistical analysis compared 
the time to relapse between treatment and 
reference cream using a Cox proportional 
hazards model. The hazard ratio (test cream 
in combination with reference cream) was 
estimated together with its 95% 2-sided confidence interval. 
The time to relapse variable for the Cox model analysis was 
defined as the time from start of the maintenance phase (Day 
1) to the time-point of relapse. The Cox regression of the 
primary analysis was stratified for country and employed the 
explanatory variables treatment, SCORAD evaluated at Visit 
1 and historic severity of AD. This model thus accounted for 
censoring as well as explanatory variables.
The Kaplan–Meier estimation was used to estimate the dist-
ribution of time to relapse (25). The Kaplan–Meier estimation 
is a simpler model that does not require the assumption of pro-
portional hazards; conversely, it does not adjust for explanatory 
variables apart from treatment.
The absolute risk reduction was calculated as the difference 
between the proportion of patients with eczema relapse treated 
with reference cream and the proportion of patients with eczema 
relapse treated with test cream. The relative risk was calculated as 
the ratio of the proportion of patients with eczema relapse treated 
with reference cream and the proportion of patients with eczema 
relapse treated with test cream. The relative risk reduction was 
calculated as the absolute risk reduction divided by the proportion 
of patients with eczema relapse treated with reference cream.
QoL was assessed using the EQ-5D™ questionnaire, the 5 
dimensions were graded by the patient according to level of 
severity and using the VAS. In addition, the historic severity 
of AD was determined and recorded according to Rajka & 
Langeland (22).
A blind review of the data was performed prior to code 
breaking.
RESULTS
Patient disposition and demographics
A total of 198 patients were screened successfully, 
172 patients were randomized and 87 received ≥ 1 
dose of test cream and 85 received ≥ 1 dose of re-
ference cream (Fig. 1). Baseline demographics, AD 
characteristics (years since diagnosis of AD, number 
of relapses during the last 12 months and severity of 
eczema) and medications were well balanced across 
the 2 treatment arms (Table I). In the test cream group 
3 patients discontinued due to lost to follow-up and 
one patient used medication not allowed in the study. 
In the reference cream group 3 patients discontinued 
due to lost to follow-up, one patient discontinued due 
to an AE (folliculitis) and 2 patients used non-allowed 
medication (Fig. 1). In order to determine the historic 
severity of AD, the criteria set by Rajka & Langeland 
were used. The median score of severity when entering 
the study was 6.00 in both groups, and was classified 
as moderate according to Rajka & Langeland (22). 
The full analysis set (FAS) was used as primary 
analysis set. Confirmatory analysis was conducted on 
the per protocol set (PPS). Patients not experiencing a 
relapse of eczema were clinically evaluated at 180 ± 14 
days. All 172 patients who were diagnosed with AD and 
randomized for the maintenance phase were included 
in the FAS. Patients without major protocol violations 
were included in the PPS, in total 162 patients (83 test 
cream, 79 reference cream). Ten patients (4 test cream, 
6 reference cream) were not included in the PPS. The 
safety set included 172 patients (87 test cream group, 
85 reference cream group). 
Screened 
n=198 
Randomised 
n=172             
Screening failures n=26 
Test  cream 
n=87 
Reference cream   
n=85 
Completed   
n=81 
Completed   
n=84 
Discontinued:   
Lost to follow-up n=3 
Discontinued: 
Lost to follow-up n=3 
Adverse event n=1 
Lost to prohibited 
medication n=1 
Lost to prohibited 
medication n=2 
Fig. 1. Patient flow chart.
Table I. Patient demographics and other baseline characteristics, 
safety analysis set
Variable
Test 
cream 
(n = 87)
Reference 
cream 
(n = 85)
Total 
(n = 172)
Age, yearsa, 30 (18–66) 28 (18–82) 28 (18–82)
Sex: Female, n (%) 49 (56.3) 52 (61.2) 101 (58.7)
Race, n (%)
Asian 1 (1.1) 1 (1.2) 2 (1.2)
Black 1 (1.1) 1 (0.6)
Other 2 (2.3) 2 (1.2)
Caucasian 83 (95.4) 84 (98.8) 167 (97.1)
Years since diagnosis of ADa 26 (0–64) 24 (0–62) 25 (0–64)
Relapses during previous 12 monthsa 5 (0–20) 4 (1–96) 4 (0–96)
Severity of eczema (Rajka & 
Langeland – score summationa
6 (3–9) 6 (3–9) 6 (3–9)
aMedian (min–max). AD: atopic dermatitis.
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Primary efficacy endpoint
In FAS there was a clear effect of treatment 
(the null hypothesis of no difference was 
rejected) as the hazard ratio was signifi-
cantly different from 1 (test cream 0.634, 
p = 0.0110) (Table II). Similar results were 
seen in the PPS (p = 0.0250) (Table II). 
The risk of eczema relapse at any point in 
time was reduced when using the test cream 
compared with the reference cream. The risk 
was reduced by about 37% (95% CI) and 
33% (95% CI) for the FAS and PPS popula-
tions, respectively. Supportive analysis using 
proportional hazard regression (FAS) agreed 
with the primary analysis (Table SI1). Similar 
results were seen in the PPS (Table SI1).
Secondary efficacy endpoints 
Time to atopic eczema relapse was eva-
luated using the Kaplan–Meier estimator 
(Fig. 2). In FAS there was a statistically 
significant effect of treatment (p = 0.0129). The test 
cream showed a statistically significantly prolonged 
estimated median time to relapse compared with the 
reference cream (22 days vs. 15 days, p = 0.0129) (Ta-
ble SII1). In PPS, the median time to relapse was the 
same as in FAS (p = 0.0311) (Table SII1). At day 180, 
26.4% of the patients using the test cream were still 
eczema-free, compared with 9.9% using the reference 
cream (Table III). Using the actuarial method at day 
180, 23.9% and 9.9% of the patients in the test cream 
and the reference cream groups, respectively, were still 
eczema free (Table III). In the maintenance phase the 
absolute risk reduction of relapse when treated with the 
test cream compared with treatment with the reference 
cream was 13.7% at day 28 and 14.0% at day 180. The 
relative risk reduction was 18.3% at day 28 and 15.6% 
at day 180 (Table SIII1). Similar results were seen in 
the PPS (Table SIII1). Quality of life increased during 
the eczema-free periods (Table IV). Cream consump-
tion was measured by weight and the median values 
for the total consumption were 347.0 g and 353.0 g for 
the test cream and the reference cream, respectively. 
Safety 
The number of patients experiencing any AE was simi-
lar between the 2 groups (Table SIV1). The majority of 
the 192 AEs recorded were of mild to moderate inten-
sity and were judged by the investigator as unrelated 
to study treatment. In total, 7 eczemas were reported as 
AE. In the test cream group, 6 AEs (3 cases of pruritus, 
1 eye discharge, 1 erythema and 1 burning sensation) 
were judged to be possibly related to the study treat-
ment. In the reference group 5 AEs (1 case of eczema, 
1 rosacea, 1 erythema, 1 pain and 1 folliculitis) were 
judged to be possibly related to the study treatment 
and 1 AE (pruritus) was judged to be probably related 
to study treatment. Three severe AEs were reported, 
but only one was judged by the investigator to be pos-
sibly related to the study treatment (test cream group, 
burning sensation in the neck). Only one serious AE 
(prostate infection) was reported in the study, this oc-
curred in the reference cream group and was judged 
by the investigator as unrelated to the study treatment. 
DISCUSSION
This randomized clinical study of patients with AD 
met its primary efficacy endpoint by demonstrating 
Table II. Proportional hazard regression (full analysis set (FAS), per protocol set (PPS))
Covariate
FAS PPS
p-value Hazard ratio 95% CI of hazard ratio p-value Hazard ratio 95% CI of hazard ratio
Test cream 0.0110 0.634 0.446, 0.901 0.0250 0.667 0.467, 0.950
Screening SCORing atopic dermatitis 0.0243 1.022 1.003, 1.041 0.0323 1.021 1.002, 1.040
Historic atopic dermatitis 0.5052 0.945 0.799, 1.117 0.4857 0.942 0.796, 1.114
95% CI: 95% confidence interval.
Fig. 2. Kaplan–Meier plot of time to recurrence of eczema in the test and reference 
cream treatment groups (full analysis set). The numbers of subjects at risk are shown 
below the horizontal axis.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2051
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that the hazard ratio was significantly different from 
one, and that the risk of an eczema relapse was reduced 
by approximately 37% at any time-point when using 
the test cream compared with the reference cream. 
Almost 3 times more patients (26% vs. 10%) treated 
with the test cream completed the whole maintenance 
phase of 6 months without a single relapse. The data 
suggest that 1 out of 4 patients diagnosed with AD and 
treated by a dermatologist could manage their disease 
with this mild maintenance treatment for 6 months or 
even longer. These findings demonstrate that patients 
with AD could delay eczema relapse by the regular 
use of the urea-containing cream compared with a 
reference cream. The median time to relapse showed 
an almost 50% increase between the test cream and the 
reference cream (22 days vs. 15 days, respectively). 
A previous study on patients with controlled AD sho-
wed that moisturizer treatment prolonged the time to 
eczema-relapse from 30 days in the untreated group 
to more than 180 days in the moisturizer group (20). 
The differences in number of days to relapse between 
the 2 studies are probably due to differences in study 
features, type/location and severity of eczemas of 
the included patients and even seasonal timing of the 
studies. Nonetheless, both studies suggest that proper 
moisturizing-therapy prolongs the eczema-free periods 
and reduces the need for topical corticosteroids or 
calcineurin inhibitors.
It is also evident from the present study that moisturi-
zers are different, not only from cosmetic perspectives, 
but also when it comes to functional properties; those 
with barrier-strengthening effects may be superior to 
those without barrier-strengthening qualities in main-
taining a healthy-appearing skin in eczema-patients. 
The active ingredient urea in the present test cream 
has been linked to barrier-strengthening properties 
in previous studies (26, 27), but notably not all urea-
formulations improve skin barrier function (13). This is 
probably due to the excipients used, such as emulsifiers, 
lipids, pH-adjusters, chelators and preservatives, which 
also may affect the skin and the penetration of urea into 
the skin. Furthermore, the stability of urea also needs 
to be taken into account in order to prevent potential 
formation of ammonia in the cream. 
There is a wide range of moisturizers on the market, 
but scientific evidence of their clinical benefit and the 
economic implications for healthcare systems in the 
treatment of AD are scarce (28). It is therefore important 
to gain clinical study data about the efficacy of different 
moisturizers in the treatment of AD. Results from such 
trials would help physicians and patients to choose 
moisturizer treatments that have proved clinically ef-
fective in AD. The effect on skin barrier and cream 
application has also been studied in children at risk for 
AD and dry skin (29–31).
In this study, effective anti-inflammatory treatment 
with topical corticosteroids before randomization was 
used to suppress the inflammation present in AD skin 
followed by a regular maintenance treatment with a 
moisturizer. This treatment protocol is in line with com-
mon clinical practise in many countries. To our know-
ledge this is the first study comparing a urea-containing 
moisturizer with a regular moisturizer containing no 
barrier-strengthening ingredients in this maintenance 
treatment strategy.
In conclusion, the present double-blind clinical study 
demonstrates that maintenance treatment with the 
barrier-strengthening urea-containing moisturizer was 
superior to a reference cream in delaying the time to 
relapse of eczema in AD patients. Treatment with the 
test cream was safe and well tolerated in the treatment 
of patients with AD.
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